Protagonist Therapeutics (PTGX) Accumulated Depreciation (2015 - 2026)

Protagonist Therapeutics has disclosed Accumulated Depreciation across 12 years of filings, most recently posting $8.7 million for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $8.7 million, up 19.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (up 19.91% YoY), and the FY2025 annual result was $8.3 million, up 18.19% from the prior year.
• Accumulated Depreciation came in at $8.7 million for Q1 2026 at Protagonist Therapeutics, up from $8.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $8.7 million in Q1 2026 to a low of $4.5 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $6.5 million (2024), against an average of $6.5 million.
• Across the five-year window, Accumulated Depreciation rose 23.39% in 2022 and grew 12.43% in 2025, its largest moves.
• Protagonist Therapeutics' Accumulated Depreciation stood at $5.3 million in 2022, then advanced by 18.65% to $6.2 million in 2023, then climbed by 12.85% to $7.0 million in 2024, then increased by 18.19% to $8.3 million in 2025, then grew by 4.89% to $8.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $8.7 million (Q1 2026), $8.3 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.